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1  | INTRODUC TION
Tumor dormancy is classically defined as the arrest of tumor growth 
in the primary site or in metastatic dissemination. The concept of 
dormancy is derived from clinical findings that cancer recurs sev-
eral years or even decades after surgical resection of the primary 
tumor, especially in breast and prostate cancers.1,2 In tumor mass 
dormancy, there is a balance between the increase in cancer cells 
by proliferation and the decrease by cell death; whereas, in cellu-
lar dormancy, cancer cells are in a quiescent state (Figure 1). Here, 
we introduce the clinical relevancy and the mechanisms underlying 
tumor dormancy.
2  | CLINIC AL INSIGHTS
Breast cancers are divided into several subgroups based on re-
ceptor expression and proliferation activity. Relapse- free sur-
vival times differ among the subtypes. In the human epidermal 
growth factor receptor 2 (HER2)- positive or triple- negative sub-
types, which have high proliferation activity, the latent periods 
are shorter than for other subtypes. In these aggressive tu-
mors, the frequency of late recurrence after 5 years is rather 
reduced3,4 compared with other subtypes that may recur even 
after 20 years.5,6 Estrogen receptor (ER)- positive breast can-
cer is a clinical model of late recurrence. A clinical study was 
carried out evaluating adjuvant therapy with tamoxifen against 
ER- positive breast cancer.7 Continuing tamoxifen for 10 years 
rather than stopping at 5 years further reduced recurrence and 
mortality, particularly after 10 years. These results indicate that 
ER- positive cancer cells could be dormant and survive for more 
than 5 years; thus, prolonged treatment is required. Recurrences 
after long- term latency are also reported in other cancers, such 
as melanoma and renal cell carcinoma.8,9 In prostate cancer, 
there are some cases in which serum levels of prostate specific 
antigen (PSA) increase without apparent recurrence of the tumor 
after primary therapy; this is called “PSA recurrence”. The actual 
recurrences occur an average of 8 years after PSA recurrence.10 
Thus, in cases of such late recurrence, cancer cells could have 
already disseminated at the time of or before surgical removal of 
the original tumors, and clinically recurred after being dormant 
for years.11
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The idea of tumor dormancy originated from clinical findings that recurrence of can-
cer occurs several years or even several decades after surgical resection of the pri-
mary tumor. Tumor mass dormancy was proposed as a model, where there is equal 
balance between increases in the number of cancer cells by proliferation and de-
creases as a result of cell death. Tumor mass dormancy includes angiogenic dormancy 
and immune- mediated dormancy. Another emerging type of tumor dormancy is cel-
lular dormancy in which cancer cells are in a quiescent state. Cellular dormancy is 
induced by cues such as the extracellular matrix environment, metastatic niches, a 
hypoxic microenvironment, and endoplasmic reticulum stress. Even the oncogenic 
pathways, on which active cancer cells depend for survival and growth, are sup-
pressed in the dormant state. As tumor dormancy is one of the mechanisms of resist-
ance against various cancer therapies, targeting dormant cancer cells should be 
considered for future treatment strategies.
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3  | TUMOR MA SS DORMANCY
To explain late recurrence, a model of “tumor mass dormancy” was 
proposed that assumed the balance between the increase in cancer 
cells by proliferation and the decrease by cell death was at equilib-
rium. Tumor mass dormancy can be achieved by two different mech-
anisms; angiogenic dormancy and immunomediated dormancy.
3.1 | Angiogenic dormancy
To support active proliferation, cancer cells consume large amounts 
of energy resources. To meet this necessity, tumor growth must be 
accompanied by the generation of a new network of blood vessels 
or angiogenesis.12 Angiogenesis is finely regulated by pro- angiogenic 
factors and anti- angiogenic factors.13 After the angiogenic switch, 
when the balance tilts to the pro- angiogenic side, a tumor enters into 
the progression phase.14 Before the angiogenic switch, increased 
numbers of cancer cells cause cell death in a region distant from pre- 
existing blood vessels because of a lack of oxygen and nutrients. The 
equilibrium between proliferation and death of cancer cells is called 
angiogenic dormancy. Involvement of angiogenic dormancy in the 
regulation of tumor growth was demonstrated in a large number of 
studies using mouse models.15-17
3.2 | Immunomediated dormancy
Immune- surveillance has long been known as a critical factor for 
suppression of tumor development and growth, and tumor cells in 
established tumors acquire the ability of immune- evasion.18,19 The 
immune system plays critical roles not only in avoiding the early 
establishment of tumors,20-22 but also in tumor mass dormancy. 
Using a spontaneous melanoma model in metallothionein (MT)- ret/
AAD mice, Eyles et al23,24 showed that CD8+ T cells are involved in 
the maintenance of tumor dormancy at the metastatic site. In this 
model, suppression of the immune system by CD8+ antibody sig-
nificantly promoted metastatic outgrowth. Genome- wide single- 
nucleotide polymorphism profiling showed that the patterns of 
genetic alterations are highly shared among primary and metastatic 
sites, indicating that metastases could be derived from tumor cells 
that disseminated from the primary tumor at an early time point. 
These results suggested that disseminated tumor cells would be dor-
mant and avoid immune- surveillance, and escape from the immune 
system resulted in metastatic outgrowth. Liang et al25 reported that 
an essential role for immune cells and their cytokines in suppressing 
tumor cell regrowth after irradiation and the disturbance of immune 
cells reversed the post- radiation equilibrium.
4  | CELLUL AR DORMANCY
Cellular dormancy is another model of tumor dormancy.26,27 Cellular 
dormancy is characterized by three features: (i) minimum prolifera-
tion; (ii) minimum death; and (iii) reversibility (Figure 1). Dormancy 
is ubiquitously found in living organisms, including bacteria, yeast, 
insects, and mammals as a survival strategy against a deteriorated 
environment. At the cellular level, the dormant status is observed in 
tissue stem cells28 and cancer. Cellular dormancy of cancer has mainly 
been studied in the context of late recurrence, especially  metastasis, 
in which the microenvironment of the metastasis site plays a critical 
role. However, cellular dormancy can also exist in tumors growing at 
F IGURE  1 Tumor mass dormancy and 
cellular dormancy. The balance between 
the growth and death of cancer cells is 
illustrated. When the balance between 
growth and death is equal, the tumor 
is in tumor mass dormancy. In cellular 
dormancy, both growth and death are 
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the primary site; for example, in the hypoxic regions (Figure 2). Given 
that dormant cells exist in tumors, they are likely resistant to conven-
tional therapies such as anticancer drugs and radiation, which target 
actively proliferating cells. Various mechanisms of cellular dormancy 
have been reported (Figure 3).
4.1 | Extracellular matrix and dormancy
The microenvironment of the metastatic site in a distant organ should 
not be the same as that of the original tumor, and in such an aberrant 
milieu, cancer cells die or become dormant. The extracellular matrix 
is an important microenvironmental factor. Aguirre- Ghiso et al29 re-
ported that the ratio of active ERK and p38MAPK by attachment to 
the extracellular matrix is the molecular switch for cellular dormancy. 
Proliferation of human epidermoid carcinoma HEp3 cells is regulated 
by two pathways: (i) activation of ERK by urokinase- plasminogen 
activator receptor (uPAR) and α5β1 integrin and; (ii) suppression of 
p38MAPK by fibronectin.30 When one of the pathways is impaired, 
the balance between ERK and p38MAPK is tilted to the growth sup-
pression side and, consequently, HEp3 cells become dormant. By 
blocking p38MAPK, cancer cells are extricated from dormancy and 
resume proliferation.31 In breast cancer, inhibition of β1 integrin in-
duced dormancy in vitro and in vivo.32,33 The mouse breast cancer 
cell lines, D2.0R and D2A1, both grow exponentially in 2- D culture 
conditions, but D2.0R fails to grow in 3- D cultures and become dor-
mant; this is compatible with the in vivo results that D2A1 forms lung 
F IGURE  2 Cancer cells in 
hypoxic regions are inactive. 
Immunohistochemistry of a mouse 
xenograft tumor, generated by s.c. 
injection of HCT116, a colon cancer cell 
line (reprinted from Okuyama et al54). 
Primary antibodies are indicated for each 
panel. Pimonidazole staining (green) 
represents hypoxic regions; CD31, blood 
vessels; BrdU, proliferation; pS6, mTORC1 
activity. Areas distant from the blood 
vessels, including the pimonidazole- 
positive regions, are negative for BrdU, 
pS6, and MYC. Scale bar, 100 μm
F IGURE  3 Mechanisms of cellular 
dormancy. There are various mechanisms 
underlying cellular dormancy. Black thin 
arrows, stimulation; blue thin arrows, 
intracellular signal; thick orange and 
blue arrows, up and down regulation, 
respectively, in terms of protein levels or 
activation of the molecule or the signal. 
EGFR, epidermal growth factor receptor; 
ER, endoplasmic reticulum; HER, human 
epidermal growth factor receptor; 
HIGD1A, hypoxia- inducible gene domain 
family member 1A; mut, active mutant; 
P, phosphorylation; TGFβ2, transforming 
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metastasis within short periods, whereas D2.0R has a long latency.34 
D2A1 cells proliferate in 3- D cultures by producing fibronectin and 
forming actin stress fibers through activation of β1 integrin. Thus, 
the interaction between the extracellular matrix and cancer cells 
plays an important role in cellular dormancy.
4.2 | Metastatic niche and dormancy
Prostate cancer cell lines can be dormant when cocultured with 
the pre- osteoblastic cell line, MC3T3- E1. Activated transforming 
growth factor beta- 2 (TGFβ2) signaling through Axl and Gas6, a li-
gand of Axl secreted by osteoblasts, plays a critical role in the induc-
tion of dormancy.35 Bone- lining cells can be a niche (endosteal niche) 
for myeloma cells. Using in vivo imaging, Lawson et al36 showed that 
myeloma cells become dormant after attachment to the bone- lining 
cells. Remodeling of the bone microenvironment by osteoclasts 
forces the myeloma cells to exit from dormancy and resume prolif-
eration. Similarly, tumor necrosis factor alpha (TNF- α) and interleu-
kin (IL)- 6 remodel the bone microenvironment to cue the dormant 
metastatic breast cancer cells in the bone marrow to resume pro-
liferation.37 Using coculture of breast cancer cells and endothelial 
cells, Ghajar et al38 showed that cancer cells become dormant when 
thrombospondin- 1 is produced by the stable microvasculature. 
Downregulation of CXCR4 in lung metastatic sites was also associ-
ated with dormant phenotype of a breast cancer cell line.39
4.3 | Hypoxic microenvironment and dormancy
Disordered proliferation of cancer cells and disorganized angiogen-
esis make the cancer microenvironment hypoxic. Consumption of 
oxygen by tumor cells plays a critical role in generating a hypoxic 
microenvironment.40 Hypoxia induces a malignant phenotype and 
therapy resistance in cancer.41 We reported that vascular endothe-
lial growth factor (Vegf ) is necessary for angiogenesis and the 
formation of pancreatic islet cell tumors in transgenic RIP1- Tag2 
mice,42 whereas tumors still exist in the Vegf null RIP1- Tag2 mice 
in an hypoxia- inducible factor (HIF)1α- dependent way.43 The resid-
ual tumors are highly hypoxic with decreased proliferation and cell 
death. Both genetic and pharmacological inhibition of angiogenesis 
result in the tumors having an invasive phenotype.44 Using cell track-
ing experiments, Harada et al45 showed that the hypoxic cells are the 
origin of recurrence after irradiation in vivo.
The transcription factor HIF plays a central role in acute hypoxic 
response in cancer cells.46 Acute hypoxic responses have been inten-
sively studied, using established cell lines fully supplied with nutrients 
except for oxygen for a short period, from several hours to 48 hours. 
Under such acute hypoxic conditions, glucose consumption drasti-
cally increases because of activated glycolysis (Figure 4). Under a mi-
croenvironment in which the glucose supply is limited, it is not likely 
that cancer cells will continue to consume large amounts of glucose. 
Thus, there should be other mechanisms different from the typical 
acute hypoxic response for the dormant cancer cells in hypoxia.
A pancreatic cancer cell line, AsPC- 1, was dormant in chronic 
hypoxia during in vitro experiments.40 The consumption of en-
ergy resources, such as oxygen and glucose, and ATP turnover are 
decreased in the dormant state. In contrast to the acute hypoxic 
response, the production of lactate, an end- product of glycolysis, 
also decreased. Suppression of AKT activity is necessary for the 
dormancy of AsPC- 1 cells, as cells with forced expression of the 
active form of AKT could not be dormant, continued to consume 
energy resources, and died under chronic hypoxic conditions. Thus, 
suppressing cellular activity under a deteriorated microenvironment 
is beneficial for cancer cell survival.
Hypoxia- inducible gene domain family member 1A (HIGD1A) is 
expressed near the necrotic region of solid tumors. As the HIGD1A 
promoter is methylated, the gene is not induced in hypoxia alone. 
Under glucose- deprived conditions, DNA methyltransferase ac-
tivity is suppressed, the HIGD1A promoter is demethylated, and 
F IGURE  4 Glycolysis and oxidative 
phosphorylation in dormant cancer 
cells. Activation status of the metabolic 
pathways is expressed as thickening 
of arrows. Amount of ATP produced 
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HIGD1A is induced. HIGD1A suppresses oxidative phosphory-
lation, activates AMPK, and suppresses reactive oxygen species 
(ROS) production. Consequently, HIGD1A supports the survival 
of cancer cells under severely hypoxic conditions.47 The orphan 
nuclear receptor, NR2F1, plays a role in the maintenance of dor-
mancy through SOX9, PARβ, and CDK inhibitors in HEp3 cells.48 
Using patient- derived xenograft models, Fluegen et al49 reported 
that an increase of p27 through NR2F1 and HIF1α is necessary for 
induction of dormancy in disseminated tumor cells using patient- 
derived xenograft models.
4.4 | Experimental platform for studying cellular 
dormancy of cancer in vitro
Establishing a model system has long been a critical concern for 
studying tumor dormancy in vitro. Recently, we developed a novel 
primary culture system of cancer cells, the cancer tissue- originated 
spheroid (CTOS) method. The principle of the CTOS method is to 
maintain cell- cell contact throughout the preparation and culture 
processes. CTOS retains the characteristics of the original patients’ 
tumors.50 In addition, CTOS can be reversibly dormant for at least 
7 days in hypoxia without growth factor stimulation for colorectal 
cancer.40,51 All of the examined CTOS derived from different pa-
tients can be dormant, suggesting that cellular dormancy is a com-
mon feature of cancer cells and is not restricted to particular cell 
lines.
4.5 | Suppression of the oncogenic pathway
The oncogene MYC is one of the most frequently dysregulated genes 
in many cancers.52 In mice with liver tissue- specific tet- off MYC gene 
expression, MYC is overexpressed in the absence of doxorubicin 
(Dox) treatment, and tumors are generated in the liver.53 After tumor 
formation, when MYC is inactivated by Dox treatment, the tumors 
stop growing and the cells revert to a normal liver cell appearance. 
After the withdrawal of Dox, tumor cells showed massive regrowth 
with reactivation of MYC. Interestingly, array comparative genomic 
hybridization analysis showed that the pattern of chromosomal gain 
and loss is almost the same between primary and recurrent tumors, 
indicating that the regrown tumor after MYC- reactivation is not a 
de novo tumor but derived from the same clone as the tumors be-
fore MYC inactivation. These results suggest that the tumor cells are 
in a dormant state during MYC inactivation. Thus, inhibition of the 
oncogenic pathway, MYC in this case, induces dormancy.
MYC activation stimulates both oxygen and glucose consump-
tion.54 We showed that MYC protein levels drastically decreased 
under glucose- and oxygen- deprived conditions through enhance-
ment of protein degradation. Cell death of colorectal cancer HCT116 
cells is alleviated by suppression of MYC under prolonged glucose- 
and oxygen- deprived conditions. MYC levels are frequently in-
creased in colorectal cancer55 and decreased in hypoxia in CTOS (M. 
Inoue, unpubl. data). Regulation of MYC levels might also be involved 
in the induction of dormancy.
A driver mutation is a mutation within a gene that plays a critical 
role in cancer development and progression. Blocking the pathway 
of the driver mutation is the basis of molecular- targeting therapy. We 
reported that CTOS from non- small cell lung cancer patients with 
epidermal growth factor receptor (EGFR) mutations can be dormant 
in hypoxic conditions.51 Intracellular signaling of the EGFR pathway 
is suppressed in dormancy, whereas constitutive phosphorylation of 
EGFR is sustained. These dormant CTOS were resistant to an EGFR 
tyrosine kinase inhibitor. Unlike EGFR, phosphorylation of the ERBB 
family members HER2 and HER3 were remarkably suppressed. The 
intrinsic inhibitor of EGFR, MIG6 (ERRFI1/RALT/Gene33), blocks di-
merization of ERBB family members by binding to the intracellular 
domain of EGFR. MIG6 is induced by hypoxia, and is necessary for 
dormancy in lung cancer cells harboring EGFR active mutations. In 
the Wnt1- inducible fibroblast growth factor receptor (FGFR)- driven 
breast cancer model, tumors become dormant when treated with 
FGFR inhibitors.56 Eventually, the tumors become resistant to the 
FGFR inhibitors by activation of EGFR. In a Dox- inducible MMTV 
Neu mouse model, a decrease in HER2 signaling by withdrawal of 
Dox led to the tumor cells being dormant. Some of the cancer cells 
activated Notch signaling and resumed proliferation.57
Human papillomavirus is an oncogenic virus, and the E6/E7 prod-
uct is important for oncogenesis. Cellular senescence is induced by 
suppression of E6/E7 under normoxic conditions, whereas cellular 
dormancy is induced under hypoxic conditions.58 Thus, suppression 
of the driver pathway leads to cancer cell death or senescence under 
the active state but not under the dormant state. Cellular dormancy 
of cancer cells is not a passive response; rather, it is regulated by 
active mechanisms.
4.6 | Endoplasmic reticulum stress and dormancy
As mentioned above, some cells can be dormant only under some 
conditions. To be dormant, there should be a particular cellular con-
text or cue, such as a hypoxic response. Another signal may be endo-
plasmic reticulum (ER) stress. In actively dividing cancer cells, protein 
synthesis that requires large amounts of energy resources is pro-
moted. Protein synthesis and the key molecule, mTORC1, are down-
regulated in cancer cells cultured in hypoxia.59 When a colorectal 
cancer cell line, COLO320, was stimulated by insulin- like growth 
factor (IGF) under hypoxic conditions, robust apoptosis was induced 
through an augmented ER stress response.60 Impaired protein fold-
ing under hypoxic conditions is responsible for the ER stress, and IGF 
might induce ER stress by stimulating aberrant protein synthesis and 
consequent cell death. Thus, too much ER stress must be avoided. 
Ranganathan et al61 reported that activation of p38 MAPK through 
ER stress is critical for induction of dormancy.
5  | FINAL REMARKS
Although the phenomenon of dormancy is becoming increasingly 
recognized in the field of cancer research, the mechanisms for it are 
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still largely unknown. One of the reasons is that “dormancy” includes 
many different states that depend on cell type; nutrient levels, oxy-
gen, and growth factors; extracellular matrix; and so on. Even if the 
final status is the same “dormancy”, the mechanisms of induction are 
different. Creating a model system still remains a critical issue. Recent 
advances in cell culture and imaging technology will enable detailed 
studies, although late recurrence in patients after several years or 
decades would not be the same as in mouse models or culture mod-
els. Finding specific markers of dormancy will enable cell tagging and 
cell fate tracking, which is necessary for assessing the role of dormant 
cells in various therapies. Developing drugs that disturb the induction 
of dormancy, kill dormant cells, or block regrowth might be other op-
tions for cancer therapy. Combination with current drugs, including 
molecular- targeting drugs, and radiation therapy might enhance the 
efficacy of the treatments. Recent advances in cancer immunology 
will also accelerate understanding of immunomediated dormancy.
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